Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE-HFrEF: ARNi and SGLT2i Initiation in HFrEF
NCT05989503Phase 4Completed
- Sponsor
- University of Porto
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan, empagliflozin, dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by University of Porto. Started Aug 2023; status: completed.
02
Drugs
sacubitril + valsartanempagliflozindapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05989503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989503.